Advocates Pharmaceutical & Healthcare
Advocates Ltd., Pharmaceutical & Healthcare is a global Programme Management and Technical Support Organisation based in Scotland, USA and Hong Kong. Clients include universities, virtual & start-up companies, biotechs, pharmaceutical companies, healthcare organisations and investors involved in developing cures for clinical disorders on a regional basis and with a global focus.
Since 2002, it has been our mission to “accelerate the development pathway towards healthier, extended lives through our competence and capacity to address drug development challenges”.
As a testament to this, our team of scientists, project managers & technical professionals have provided `hands on’ technical support to 17 drug development programmes from discovery to our clients required endpoint, all of which have met their development objectives, whilst maintaining focus on delivery of commercial objectives & investment opportunities.
Discovery to Market Key Services include:
· Grant Funding Support
· Technical Due Diligence / Investor Support
· Project Management
· Discovery & Pre-Clinical Support
· Pharmaceutical Development CMC
· Quality Management
· Regulatory Preparation, Submission & Liaison
· Operational / Commercial CMC
· Supplies / Logistics Management
· Clinical Support
· Medical Devices Expertise
Benefits to our Clients:
· Proven expertise of successfully managing development programmes
· Experienced in all compound classes, the majority of therapeutic areas and routes of administration
· Experts in CMC (Chemistry, Manufacturing & Controls)
· Credible relationships with national regulatory agencies
· Trustworthy relationships with funding bodies
· Bases in UK, USA & HK / trade in local currencies
· We care “caring is a powerful business advantage”
If you would like to discuss any aspect of your drug development needs please email:
Angelina Fisher at: email@example.com, alternatively, please call +44 (0) 7929 671290.
Angelina FisherDirector of Corporate Affairs
Almac provides a comprehensive range of integrated services from research through to commercialisation. Almac is a financially stable, privately owned organisation with over 3,300 employees located within the US and UK. Over 95% of work is repeat business, testament itself to the quality, innovation, efficiency and the high level of customer satisfaction provided.
Almac’s integrated solutions extend from research to commercialisation and include:
Biomarker Discovery & Development:
· Companion Diagnostic Development
· Genomic Services
· Bioinformatics Consultancy
· Proprietary Discovery Arrays
API Services & Chemical Development:
· API Development & Manufacture
· Peptide & Protein Technology
· Accelerated First in Man Solution
· Solid State Services
· Isotope Chemistry
· Preformulation & Early Stage Development
· Scale Up and Late Stage Development
· Clinical Trial Manufacture
· Contained Development & Manufacture
· Physical & Chemical Characterisation
· Method Development & Validation
· API & Drug Product Testing
· Stability Testing
Clinical Trial Supply:
· Comparator Blinding
· Packaging & Labelling
· QP Release
· Global Distribution & Supply Chain Management
· IVR / Web
· Statistical Services
· Manufacturing & Packaging
· Product Launch & Distribution
Come and see us at booth #64
Mr Rick DyerBusiness Development Manager
Dr Rob GrundyDirector Research Alliances, Almac Discovery Ltd
Mr Glyn AllsopBusiness Development Manager
Mr Simon LawrenceVP, Business Development, Galen Ltd
Ms Helen McKeeverProgramme Manager
Mr Stephen BarrManaging Director
Autifony Therapeutics Ltd
Autifony Therapeutics is developing pharmaceutical treatments for hearing disorders, which affect a significant proportion of the population. Autifony ‘s approach is focused on Kv3 potassium channel modulation, a novel mechanism of action. These ion channels regulate neuronal activity within the auditory system, and our new drugs aim to treat age related hearing loss and tinnitus. The lead programme entered Phase I clinical trials in May 2013.
Given Autifony’s focus on modulation of Kv3 channels, which have also been implicated in other neurological and psychiatric disorders, there are opportunities for Autifony to investigate these other indications with compounds with different profiles. Autifony was recently awarded Technology Strategy Board funding to progress the development of a candidate drug for the treatment of schizophrenia, working together with academic collaborators at the Universities of Manchester and Newcastle.
Autifony Therapeutics Limited was formed in 2011 as a spin-out from GlaxoSmithKline. The company is privately funded by leading venture capital investors SV Life Sciences, Imperial Innovations and Pfizer Venture Investments. Autifony’s head office is at the Imperial College Incubator in London, and has a subsidiary with medicinal chemistry and biology labs based in Verona, Italy.
Dr Barbara Domayne-HaymanChief Business Officer
Avillion was registered in London UK in December 2012 and we are fully financed by the venture capital groups Abingworth and Clarus ventues. We are a company focused on co-development and financing of late-stage programs, where we provide partners with 100% financing for regulatory approval studies with the intent of accelerating the approval of drugs in the US and the EU.
We offer partners an unique and attractive option for the advancement of their pipeline- where we incur 100% of the clinical and regulatory risk of a program, thereby enabling partners to limit their P&L burden and have an advantageous financial position (EPS preservation).
Mr Lewis CameronCEO
Dr Allison Jeynes-EllisCMO
BioIndustry Association (BIA)
Established in 1989, the BIA (BioIndustry Association) exists to encourage and promote a financially sound and thriving bioscience sector within the UK economy and concentrates its efforts on emerging enterprise and the related interests of companies with whom such enterprise trades.
With over 300 members, the BIA supports a wide range of sectors, majoring on the human health benefits of the technology and represents the interests of these innovative companies to a broad section of stakeholders from patient groups to politicians, advancing its members interests both within the UK and internationally to create a healthy UK bioscience sector which benefits society.
Mr Alastair CarringtonBusiness Development Executive
Mr Steve BatesCEO
BioPartner is your UK point of contact at Bio-Europe 2013 based at stand #68.
BioPartner is an independent, accredited trade organisation, promoting international partnering for trade, investment and collaborations with UK Life Science companies. Through the BioPartnership Programme, BioPartner assists companies to attend major international biopharma conferences by providing access to government grants and heavily discounted entry fees.
Dr Alasdair StampsExecutive Director
Naima AhmedResearch Analyst
Cambridge Bioscience is a well established, leading European distributor of life science products bringing new and exciting technologies to researchers. Working with over forty specialist suppliers around the world, we offer an innovative, extensive and diverse range of over 450,000 products, services and instruments supporting research in the areas of drug discovery, regenerative medicine, cell culture and much more.
The products and services Cambridge Bioscience offers includes:
· Ion Channel, GPCR & Kinase Profiling Services
· Primary screening & Secondary Drug Profiling Services
· Cardiac Safety Assessment
· Ion Channel & GPCR Cell Lines
· Human Tissues, TMAs & Biofluids
· Primary Cells & Cell Culture Technologies
To find out more, please meet us at the event or contact us using the details below
Tel: +44 (0)1223 316 855
Fax: +44 (0)1954 781 323
Canbex Therapeutics Ltd
Canbex is dedicated to improving the quality of life for people with multiple sclerosis (MS) and potentially other disorders, through better treatment for spasticity.
Spasticity is the sudden and uncontrollable movement of limbs and torso, and is among the most painful, damaging and debilitating symptoms of MS. Current drug treatments for spasticity are effective but are plagued by sedative and other side effects that sharply limit their usefulness.
Canbex closed a $3.2m financing round led by Merck Serono Ventures in April 2013, and its lead anti-spasticity compound, VSN16R, is set to enter Phase I safety testing. In studies to date, VSN16R shows substantially improved tolerability compared to other compounds, and is as effective against spasticity as any other agent known.
Supported by its leading London-based scientific and clinical team, Canbex believes that VSN16R has the potential to meet an important medical need, and to address a highly attractive commercial opportunity.
To find out more, please meet us at the event or contact us using the details below
Canbex Therapeutics Ltd
London BioScience Innovation Centre
2 Royal College Street
Tel: +44 (0)207 554 5872
Dr Jesse SchulmanCEO
Dr Keith PowellChairman
About Competitive Drug Development International Ltd.
CDDI is an international biotechnology and pharmaceutical consulting company, led by senior people who together have developed more than 20 products globally from discovery to market. CDDI can give support with a broad range of drug development activities across the three key disciplines of Clinical, Non-clinical and CMC.
Services include Virtual Asset Development (VAD), where CDDI provides a fully integrated development team directed by strong project leadership, Evidence Based Protocol Feasibility (ebf) for data-driven and rapid patient recruitment, and CMC services from API and formulation development of NCEs and NBEs, through to CMO management of GMP manufacturing.
Our working method is hands-on, not just consulting, which means, we don’t just advise you, but actively implement the strategies and plans that we formulate with you. For more information please visit www.cddi.co.
Dr Grahaem BrownManaging Partner
Ms Eva HurstPartner
CrystecPharma applies the latest supercritical fluid (SCF) technologies to improve the design and performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical industry, contributing to human health by enabling new and more effective therapies.
Crystec SCF technologies can be applied to both small drug molecules and biomolecules.
Our services include crystal form screening and particle design, addressing issues of poor solubility and stability, improved delivery, and product enhancement in support of lifecycle management.
We are also engaged in in-house programmes to develop improved small and large molecule therapeutic products.
Our objectives this year at BioEurope are to identify new clients wishing to enhance the performance of their small and large moilecule therapeutics as well as identifying co-development partners, for supergeneric and new drugs.